In particular, monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 pathway have resulted in favorable outcomes in advanced bladder cancer and six immune checkpoint inhibitors (ICIs) targeting this pathway were approved in 2015–2018 [7]. Here, PDCD1 is linked to urinary bladder carcinoma.